Trial
NCT00061178
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Phase IIIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Renal Cell Cancer
Intervention
rhuMAb VEGF (Bevacizumab)
Why stopped
No patients were enrolled, study cancelled before start
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-10-19